Figure 2From: Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial Survival analysis. ZOL group – patients assigned to adjuvant therapy plus intravenous zoledronic acid every four weeks. Control group – patients assigned to adjuvant therapy alone (a) Overall survival (b) Relapse-free survival.Back to article page